Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.38 |
| ▸ | FABP7 | O15540 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.34 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | PRCP | P42785 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30170466 | 1.00 | CYP19A1 (0.39) | CYP19A1FABP5FABP7KMT2APOLB | |
| SCHEMBL30856517 | 1.00 | CYP19A1 (0.39) | CYP19A1FABP5FABP7KMT2APOLB | |
| SCHEMBL19371247 | 1.00 | CYP19A1 (0.39) | CYP19A1FABP5FABP7KMT2APOLB | |
| SCHEMBL19391069 | 1.00 | CYP19A1 (0.39) | CYP19A1FABP5FABP7KMT2APOLB | |
| SCHEMBL26008578 | 0.92 | KMT2A (0.39) | CYP19A1FABP5FABP7KMT2ANPSR1 | |
| SCHEMBL26008577 | 0.92 | KMT2A (0.39) | CYP19A1FABP5FABP7KMT2ANPSR1 | |
| SCHEMBL25817021 | 0.88 | KMT2A (0.40) | CYP19A1FABP5FABP7KMT2AEPHX2 | |
| SCHEMBL3789335 | 0.84 | KMT2A (0.43) | FABP5FABP7KMT2APOLBEPHX2 | |
| SCHEMBL3783542 | 0.84 | KMT2A (0.43) | FABP5FABP7KMT2APOLBEPHX2 | |
| SCHEMBL3793423 | 0.84 | KMT2A (0.43) | FABP5FABP7KMT2APOLBEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240317729-A1 | Compounds & Methods for the Enhanced Degradation of Targeted Proteins & Other Polypeptides by an E3 Ubiquitin Ligase | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-09-26 | — | — | US | disclosed |
| US-20230233703-A1 | AMANITIN CONJUGATES | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2023-07-27 | — | — | US | disclosed |
| US-11702451-B2 | Method for synthesizing amanitins | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2023-07-18 | — | — | US | disclosed |
| US-20210138081-A1 | Amanitin Conjugates | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2021-05-13 | — | — | US | disclosed |
| US-20210130412-A1 | METHOD FOR SYNTHESIZING AMANITINS | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2021-05-06 | — | — | US | disclosed |
| US-10961277-B2 | Method for synthesizing amanitins | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2021-03-30 | — | — | US | disclosed |
| US-20210061805-A1 | NOVEL METHOD FOR SYNTHESIZING AMANITINS | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2021-03-04 | — | — | US | disclosed |
| US-10730862-B2 | Compounds and methods for the enhanced degradation of targeted proteins and other polypeptides by an E3 ubiquitin ligase | YALE UNIVERSITY (US) | 2020-08-04 | — | — | US | disclosed |
| US-20200181200-A1 | NOVEL METHOD FOR SYNTHESIZING AMANITINS | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2020-06-11 | — | — | US | disclosed |
| EP-3608317-A1 | COMPOUNDS & METHODS FOR THE ENHANCED DEGRADATION OF TARGETED PROTEINS & OTHER POLYPEPTIDES BY AN E3 UBIQUITIN LIGASE | Yale University (US) | 2020-02-12 | — | — | EP | disclosed |
| US-8076330-B2 | Dipeptidyl peptidase-IV inhibitors | AMGEN INC. (US) | 2011-12-13 | — | — | US | disclosed |
| US-8076330-B2 | Dipeptidyl peptidase-IV inhibitors | AMGEN INC. (US) | 2011-12-13 | — | — | US | disclosed |
| US-20110112051-A1 | Dipeptidyl Peptidase-IV Inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2011-05-12 | — | — | US | disclosed |
| US-20110112051-A1 | Dipeptidyl Peptidase-IV Inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2011-05-12 | — | — | US | disclosed |
| US-20100009961-A1 | DIPEPTIDYL PEPTIDASE-IV INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2010-01-14 | — | — | US | disclosed |
| US-20100009961-A1 | DIPEPTIDYL PEPTIDASE-IV INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2010-01-14 | — | — | US | disclosed |
| US-7553861-B2 | Dipeptidyl peptidase-IV inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2009-06-30 | — | — | US | disclosed |
| US-7553861-B2 | Dipeptidyl peptidase-IV inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2009-06-30 | — | — | US | disclosed |
| WO-2006116157-A9 | DIPEPTIDYL PEPTIDASE-IV INHIBITORS | ALANTOS PHARMACEUTICALS INC (US) | 2007-03-01 | — | — | WO | disclosed |
| WO-2006116157-A2 | DIPEPTIDYL PEPTIDASE-IV INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2006-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230233703-A1 | AMANITIN CONJUGATES | CD47, MTX1, SIGLEC7 | CYP19A1 4034/4885FABP5 741/4885FABP7 630/4885 |
| US-20200181200-A1 | NOVEL METHOD FOR SYNTHESIZING AMANITINS | CIAPIN1, ANXA5, AANAT | CYP19A1 1299/4885FABP5 991/4885FABP7 513/4885 |
| US-20100009961-A1 | DIPEPTIDYL PEPTIDASE-IV INHIBITORS | DPP4, DPP3, DPP7 | CYP19A1 4259/4885FABP5 540/4885FABP7 3140/4885 |
| US-10730862-B2 | Compounds and methods for the enhanced degradation of targeted proteins and other polypeptides by an E3 ubiquitin ligase | VHL, MDM2, NEDD4 | CYP19A1 3484/4885FABP5 1709/4885FABP7 2451/4885 |
| US-20210138081-A1 | Amanitin Conjugates | CD47, MTX1, SIGLEC7 | CYP19A1 4034/4885FABP5 741/4885FABP7 630/4885 |
| US-20210061805-A1 | NOVEL METHOD FOR SYNTHESIZING AMANITINS | CIAPIN1, ANXA5, ANXA6 | CYP19A1 2200/4885FABP5 1472/4885FABP7 825/4885 |
| US-10961277-B2 | Method for synthesizing amanitins | CIAPIN1, AANAT, ANXA5 | CYP19A1 1102/4885FABP5 1052/4885FABP7 530/4885 |
| US-20240317729-A1 | Compounds & Methods for the Enhanced Degradation of Targeted Proteins & Other Polypeptides by an E3 Ubiquitin Ligase | MDM2, VHL, XIAP | CYP19A1 3485/4885FABP5 1671/4885FABP7 2870/4885 |
| US-11702451-B2 | Method for synthesizing amanitins | CIAPIN1, AANAT, ANXA5 | CYP19A1 1102/4885FABP5 1052/4885FABP7 530/4885 |
| US-20210130412-A1 | METHOD FOR SYNTHESIZING AMANITINS | CIAPIN1, AANAT, ANXA5 | CYP19A1 1102/4885FABP5 1052/4885FABP7 530/4885 |
| US-20110112051-A1 | Dipeptidyl Peptidase-IV Inhibitors | DPP4, DPP3, DPP7 | CYP19A1 4259/4885FABP5 540/4885FABP7 3140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.